GlassScriptPhysician profile
Denis D Knight
NPI 1235190919
$4,206.14
in general payments reported to CMS, 2019-2025
35 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.48 · 2021: $693 · 2022: $697 · 2023: $838 · 2024: $984 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,783 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.32 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.02 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Abbvie INC. | $666.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $637.27 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $303.83 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Paratek Pharmaceuticals, INC. | $250.19 | 2023-2025 | Nuzyra, Xhance |
| Bayer Healthcare Pharmaceuticals INC. | $239.94 | 2022-2025 | |
| Abbott Laboratories | $209.83 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $170.03 | 2022-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $106.49 | 2021-2023 | Xarelto |
| Eisai INC. | $105.85 | 2021-2022 | |
| Glaxosmithkline, LLC. | $103.05 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.61 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $59.06 | 2022-2024 | Quviviq |
| Sanofi Pasteur INC. | $50.21 | 2021-2022 | |
| Pfizer INC. | $49.00 | 2022-2023 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denis Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.